Gateway Investment Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

Gateway Investment Advisers’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Buy	+4,630	New	+$348K	﹤0.01%	668
2023 Q1	–	Sell	-51,174	Closed	-$1.93M	–	531
2022 Q4	$1.93M	Buy	51,174 +975	+2%	+$41K	0.02%	308
2022 Q3	$2.22M	Sell	50,199 -48,930	-49%	-$2.06M	0.03%	303
2022 Q2	$3.67M	Hold	99,129	–	–	0.04%	262
2022 Q1	$3.67M	Buy	99,129 +14,026	+16%	+$459K	0.04%	278
2021 Q4	$2.59M	Buy	85,103 +46,971	+123%	+$1.48M	0.02%	291
2021 Q3	$1.28M	Buy	38,132 +532	+1%	+$20K	0.01%	349
2021 Q2	$1.5M	Hold	37,600	–	–	0.02%	344
2021 Q1	$1.69M	Hold	37,600	–	–	0.02%	333
2020 Q4	$2.13M	Hold	37,600	–	–	0.02%	316
2020 Q3	$1.78M	Hold	37,600	–	–	0.02%	316
2020 Q2	$2.22M	Sell	37,600 -38,876	-51%	-$2.16M	0.03%	309
2020 Q1	$3.62M	Buy	76,476 +37,513	+96%	+$2.09M	0.04%	248
2019 Q4	$2.35M	Sell	38,963 -3,283	-8%	-$196K	0.02%	329
2019 Q3	$2.53M	Buy	42,246 +803	+2%	+$52.3K	0.03%	338
2019 Q2	$2.66M	Buy	+41,443	New	+$2.93M	0.02%	334

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Gateway Investment Advisers's IONS Position: Q2 2026 in Review

Gateway Investment Advisers opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 4,630 shares worth $367K. The stake represents ﹤0.01% of the portfolio and ranks #668 among its holdings. This is a return to the name: Gateway Investment Advisers previously reported a position in IONS as recently as Q4 2022.

Gateway Investment Advisers first reported a position in IONS in Q2 2019 and has held it in 16 quarters since. The position peaked at $3.67M in Q1 2022. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Gateway Investment Advisers held 4,630 shares of Ionis Pharmaceuticals worth $367K as of Q2 2026.
Ionis Pharmaceuticals was a new Gateway Investment Advisers position in Q2 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #668 holding.
Gateway Investment Advisers first reported a position in Ionis Pharmaceuticals in Q2 2019 and has held it in 16 quarters since.
Gateway Investment Advisers's Ionis Pharmaceuticals position peaked at $3.67M in Q1 2022.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.